Balamuthia mandrillaris: pathogenesis, diagnosis, and treatment

References

• Matin A, Siddiqui R, Jayasekera S, et al. Increasing importance of Balamuthia mandrillaris. Clin Microbiol Rev. 2008;21(3):435–448.
   PubMed Web of Science ®Google Scholar
• Visvesvara GS, Moura H, Schuster FL. Pathogenic and opportunistic free-living amoebae: acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri, and Sappinia diploidea. FEMS Immunol Med Microbiol. 2007;50(1):1–26.
   PubMed Web of Science ®Google Scholar
• Siddiqui R, Khan NA. Balamuthia mandrillaris: morphology, biology, and virulence. Trop Parasitol. 2015;5(1):15.
   PubMedGoogle Scholar
• Laurie MT, White CV, Retallack H, et al. Functional assessment of 2,177 US and international drugs identifies the quinoline nitroxoline as a potent amoebicidal agent against the pathogen Balamuthia mandrillaris. mBio. 2018;9(5):e02051–18.
   PubMed Web of Science ®Google Scholar
• Yera H, Dupouy-Camet J, Jackson JW, et al. In vitro growth, cytopathic effects and clearance of monolayers by clinical isolates of Balamuthia mandrillaris in human skin cell cultures. Exp Parasitol. 2015;156:61–67.
   PubMed Web of Science ®Google Scholar
• Cope J, Puttagunta R, Gomez J, et al. Clinical features of Balamuthia mandrillaris disease in the United States, 1974–2014. In Open Forum Infect Dis. 2015;2(1):1343.
   Google Scholar
• Schuster FL, Yagi S, Gavali S, et al. Under the radar: balamuthia amebic encephalitis. Clin Infect Dis. 2009;48(7):879–887.
   PubMed Web of Science ®Google Scholar
• Laurie MT, White CV, Retallack H, et al. Repurposing the quinoline antibiotic nitroxoline to treat infections caused by the brain-eating amoeba Balamuthia mandrillaris. bioRxiv. 2018;e331785. DOI: 10.1101/331785
   Google Scholar
• Siddiqui R, Khan NA. Balamuthia amoebic encephalitis: an emerging disease with fatal consequences. Microbiol Pathogen. 2008;44(2):89–97.
   PubMed Web of Science ®Google Scholar
• Jung S, Schelper RL, Visvesvara GS, et al. Balamuthia mandrillaris meningoencephalitis in an immunocompetent patient: an unusual clinical course and a favorable outcome. Arch Path Lab Med. 2004;128(4):466–468.
   PubMed Web of Science ®Google Scholar
• Bakardjiev A, Azimi PH, Ashouri N, et al. Amebic encephalitis caused by Balamuthia mandrillaris: report of four cases. Pediatr Infect Dis J. 2003;22(5):447–453.
   PubMed Web of Science ®Google Scholar
• Katz JD, Ropper AH, Adelman L, et al. A case of Balamuthia mandrillaris meningoencephalitis. Arch Neurol. 2000;57(8):1210–1212.
   PubMedGoogle Scholar
• Denney CF, Iragui VJ, Zak LU, et al. Amebic meningoencephalitis caused by Balamuthia mandrillaris: case report and review. Clin Infect Dis. 1997;25(6):1354–1358.
   PubMed Web of Science ®Google Scholar
• Deol I, Robledo L, Meza A, et al. Encephalitis due to a free-living amoeba (Balamuthia mandrillaris): case report with literature review. Surg Neurol. 2000;53(6):611–616.
   PubMedGoogle Scholar
• Kodet R, Nohýnková E, Tichý M, et al. Amebic encephalitis caused by Balamuthia mandrillaris in a Czech child: description of the first case from Europe. Pathol Res Pract. 1998;194(6):423–429.
   PubMed Web of Science ®Google Scholar
• Martínez DY, Seas C, Bravo F, et al. Successful treatment of Balamuthia mandrillaris amoebic infection with extensive neurological and cutaneous involvement. Clin Infect Dis. 2010;51(2):e7–11.
   PubMed Web of Science ®Google Scholar
• Jayasekera S, Sissons J, Tucker J, et al. Post-mortem culture of Balamuthia mandrillaris from the brain and cerebrospinal fluid of a case of granulomatous amoebic meningoencephalitis, using human brain microvascular endothelial cells. J Med Microbiol. 2004;53(10):1007–1012.
   PubMed Web of Science ®Google Scholar
• Tavares M, da Costa JM, Carpenter SS, et al. Diagnosis of first case of Balamuthia amoebic encephalitis in Portugal by immunofluorescence and PCR. J Clin Microbiol. 2006;44(7):2660–2663.
   PubMed Web of Science ®Google Scholar
• Deetz TR, Sawyer MH, Billman G, et al. Successful treatment of Balamuthia amoebic encephalitis: presentation of 2 cases. Clin Infect Dis. 2003;37(10):1304–1312.
   PubMed Web of Science ®Google Scholar
• Pritzker AS, Kim BK, Agrawal D, et al. Fatal granulomatous amebic encephalitis caused by Balamuthia mandrillaris presenting as a skin lesion. J Am Acad Dermatol. 2004;50(2):38–41.
   Web of Science ®Google Scholar
• Huang ZH, Ferrante A, Carter RF. Serum antibodies to Balamuthia mandrillaris, a free-living amoeba recently demonstrated to cause granulomatous amoebic encephalitis. J Infect Dis. 1999;179(5):1305–1308.
   PubMed Web of Science ®Google Scholar
• Booton GC, Carmichael JR, Visvesvara GS, et al. Identification of Balamuthia mandrillaris by PCR assay using the mitochondrial 16S rRNA gene as a target. J Clin Microbiol. 2003;41(1):453–455.
   PubMed Web of Science ®Google Scholar
• Yagi S, Booton GC, Visvesvara GS, et al. Detection of Balamuthia mitochondrial 16S rRNA gene DNA in clinical specimens by PCR. J Clin Microbiol. 2005;43(7):3192–3197.
   PubMed Web of Science ®Google Scholar
• Qvarnstrom Y, Visvesvara GS, Sriram R, et al. Multiplex real-time PCR assay for simultaneous detection of Acanthamoeba spp., Balamuthia mandrillaris, and NaegleriaNaegleria fowleri. J Clin Microbiol. 2006;44(10):3589–3595.
   PubMed Web of Science ®Google Scholar
• Wilson MR, Shanbhag NM, Reid MJ, et al. Diagnosing Balamuthia mandrillaris encephalitis with metagenomic deep sequencing. Ann Neurol. 2015;78(5):722–730.
   PubMed Web of Science ®Google Scholar
• Wilson MR, Naccache SN, Samayoa E, et al. Actionable diagnosis of neuroleptospirosis by next-generation sequencing. New Eng J Med. 2014;370(25):2408–2417.
   PubMed Web of Science ®Google Scholar
• Ong TY, Khan NA, Siddiqui R. Brain-eating amoebae: predilection sites in the brain and disease outcome. J Clin Microbiol. 2017;55(7):1989–1997.
   PubMed Web of Science ®Google Scholar
• Rocha-Azevedo B, Jamerson M, Cabral GA, et al. The interaction between the amoeba Balamuthia mandrillaris and extracellular matrix glycoproteins in vitro. Parasitol. 2007;134(1):51–58.
   PubMedGoogle Scholar
• Matin A, Siddiqui R, Jung SY, et al. Balamuthia mandrillaris interactions with human brain microvascular endothelial cells in vitro. J Med Microbiol. 2007;56(8):1110–1115.
   PubMed Web of Science ®Google Scholar
• Shadrach WS, Radam E, Flieger A, et al. The pathogenic amoeba Balamuthia mandrillaris possesses cell-associated phospholipase A, lysophospholipase A, and lipase activities. Int J Med Microbiol. 2004;293:100.
   Web of Science ®Google Scholar
• Haider R. Colorimetric determination of phospholipase activities in Balamuthia mandrillaris. Am J Biochem Biotechnol. 2007;3:171–179.
   Google Scholar
• Matin A, Khan NA. Demonstration and partial characterization of ecto‐ATPase in Balamuthia mandrillaris and its possible role in the host‐cell interactions. Lett Appl Microbiol. 2008;47(4):348–354.
   PubMed Web of Science ®Google Scholar
• Kiderlen AF, Tata PS, Oezel M, et al. Cytopathogenicity of Balamuthia mandrillaris, an opportunistic causative agent of granulomatous amebic encephalitis. J Euk Microbiol. 2006;53(6):456–463.
   PubMed Web of Science ®Google Scholar
• Dunnebacke TH. The ameba Balamuthia mandrillaris feeds by entering into mammalian cells in culture. J Euk Microbiol. 2007;54(5):452–464.
   PubMed Web of Science ®Google Scholar
• Matin A, Stins M, Kim KS, et al. Balamuthia mandrillaris exhibits metalloprotease activities. FEMS Immunol Med Microbio. 2006;47(1):83–91.
   PubMedGoogle Scholar
• Jayasekera S, Matin A, Sissons J, et al. Balamuthia mandrillaris stimulates interleukin-6 release in primary human brain microvascular endothelial cells via a phosphatidylinositol 3-kinase-dependent pathway. Microb Infect. 2005;7(13):1345–1351.
   PubMed Web of Science ®Google Scholar
• de Vries HE, Blom-Roosemalen MC, van Oosten M, et al. The influence of cytokines on the integrity of the blood-brain barrier in vitro. J Neuroimmunol. 1996;64(1):37–43.
   PubMed Web of Science ®Google Scholar
• Bravo FG, Alvarez PJ, Gotuzzo E. Balamuthia mandrillaris infection of the skin and central nervous system: an emerging disease of concern to many specialties in medicine. Curr Opin Infect Dis. 2011;24(2):112–117.
   PubMed Web of Science ®Google Scholar
• Bravo FG, Cabrera J, Gotuzzo E, et al. Cutaneous manifestations of infection by free-living amebas. Vol. 6; 2006. p. 49–55. doi:10.1016/B978-0-443-06790-7.50010-7
   Google Scholar
• Cary LC, Maul E, Potter C, et al. Balamuthia mandrillaris meningoencephalitis: survival of a pediatric patient. Pediatrics. 2010;125(3):e699–703.
   PubMed Web of Science ®Google Scholar
• Girard RM, Crispim M, Stolić I, et al. An aromatic diamidine that targets kinetoplast DNA, impairs the cell cycle in Trypanosoma cruzi, and diminishes trypomastigote release from infected mammalian host cells. Antimicrob Agent Chemother. 2016;60(10):5867–5877.
   PubMed Web of Science ®Google Scholar
• Perrine D, Chenu JP, Georges P, et al. Amoebicidal efficiencies of various diamidines against two strains of Acanthamoeba polyphaga. Antimicrob Agent Chemother. 1995;39(2):339–342.
   PubMed Web of Science ®Google Scholar
• Schneider-Poetsch T, Ju J, Eyler DE, et al. Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin. Nat Chem Biol. 2010;6(3):209.
   PubMed Web of Science ®Google Scholar
• Bulsara KG, Cassagnol M. Amlodipine. In: InStatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK519508/
   Google Scholar
• Peregrine AS, Mamman M. Pharmacology of diminazene: a review. Acta Trop. 1993;54:185–203.
   PubMed Web of Science ®Google Scholar
• Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother. 2000;46(2):171–179.
   PubMed Web of Science ®Google Scholar
• Jenner P, Katzenschlager R. Apomorphine-pharmacological properties and clinical trials in Parkinson’s disease. Parkinson Relat Disord. 2016;33:S13–21.
   PubMedGoogle Scholar
• Leem SH, Park JE, Kim IS, et al. The possible mechanism of action of ciclopirox olamine in the yeast Saccharomyces cerevisiae. Mol Cell. 2003;15(1):55–61.
   Google Scholar
• Pinto-Martinez AK, Rodriguez-Durán J, Serrano-Martin X, et al. Mechanism of action of miltefosine on Leishmania donovani involves the impairment of acidocalcisome function and the activation of the sphingosine-dependent plasma membrane Ca2+ channel. Antimicrob Agent Chemother. 2018;62(1):e01614–01617.
   PubMed Web of Science ®Google Scholar
• Aqeel Y, Iqbal J, Siddiqui R, et al. Anti-Acanthamoebic properties of resveratrol and demethoxycurcumin. Exp Parasitol. 2012;132(4):519–523.
   PubMed Web of Science ®Google Scholar
• David JM, Rajasekaran AK, Gramicidin A. A new mission for an old antibiotic. J Kid Can VHL. 2015;2(1):15.
   PubMed Web of Science ®Google Scholar
• Garris PA, Budygin EA, Phillips PE, et al. A role for presynaptic mechanisms in the actions of nomifensine and haloperidol. Neurosci. 2003;118(3):819–829.
   PubMed Web of Science ®Google Scholar
• Ooms LA, Degryse AD, Janssen PA. Mechanisms of action of loperamide. Scand J Gastroenterol. 1984;96:145–155.
   Google Scholar
• Noor A, Pellegrini MV Antifungal, membrane function inhibitors (Amphotericin B). In: InStatPearls. Treasure Island (FL): StatPearls Publishing; 2019. https://www.ncbi.nlm.nih.gov/books/NBK482327/
   Google Scholar
• Saef MA, Saadabadi A Protriptyline. In: InStatPearls. Treasure Island (FL): StatPearls Publishing; 2019. https://www.ncbi.nlm.nih.gov/books/NBK499828/
   Google Scholar
• Din L, Preuss CV Prochlorperazine. In: InStatPearls. Treasure Island (FL): StatPearls Publishing; 2019. https://www.ncbi.nlm.nih.gov/books/NBK537083/
   Google Scholar
• Loose DS, Kan PB, Hirst MA, et al. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest. 1983;71(5):1495–1499.
   PubMed Web of Science ®Google Scholar
• Wright P, Stern J, Phelan M. Core psychiatry. 3rd ed. Amsterdam, The Netherlands: Elsevier; 2012. p. 680. ISBN: 9780702033971
   Google Scholar
• Kresken M, Körber-Irrgang B. In vitro activity of nitroxoline against Escherichia coli urine isolates from outpatient departments in Germany. Antimicrob Agent Chemother. 2014;58(11):7019–7020.
   PubMed Web of Science ®Google Scholar
• Goddette DW, Frieden C. Actin polymerization. The mechanism of action of cytochalasin D. J Biol Chem. 1986;261(34):15974–15980.
   PubMed Web of Science ®Google Scholar
• Varoni EM, Lo Faro AF, Sharifi-Rad J, et al. Anticancer molecular mechanisms of resveratrol. Front Nutri. 2016;3:8.
   PubMed Web of Science ®Google Scholar
• Vicens Q, Westhof E. Crystal structure of paromomycin docked into the eubacterial ribosomal decoding A site. Structure. 2001;9(8):647–658.
   PubMed Web of Science ®Google Scholar
• Schuster FL, Visvesvara GS. Axenic growth and drug sensitivity studies of Balamuthia mandrillaris, an agent of amebic meningoencephalitis in humans and other animals. J Clin Microbio. 1996;34(2):385–388.
   PubMed Web of Science ®Google Scholar
• Siddiqui R, Matin A, Warhurst D, et al. Effect of antimicrobial compounds on Balamuthia mandrillaris encystment and human brain microvascular endothelial cell cytopathogenicity. Antimicrob Agent Chemother. 2007;51(12):4471–4473.
   PubMed Web of Science ®Google Scholar
• Kalsoom H, Baig AM, Khan NA, et al. Laboratory testing of clinically approved drugs against Balamuthia mandrillaris. World J Microbiol Biotech. 2014;30(9):2337–2342.
   PubMed Web of Science ®Google Scholar
• Ahmad AF, Heaselgrave W, Andrew PW, et al. The in vitro efficacy of antimicrobial agents against the pathogenic free‐living amoeba Balamuthia mandrillaris. J Euk Microbiol. 2013;60(5):539–543.
   PubMed Web of Science ®Google Scholar
• Trimble MJ, Mlynárčik P, Kolář M, et al. Polymyxin: alternative mechanisms of action and resistance. Cold Spring Harbor Perspect Med. 2016;6(10):a025288.
   PubMed Web of Science ®Google Scholar
• Schuster FL, Guglielmo BJ, Visvesvara GS. In‐vitro activity of miltefosine and voriconazole on clinical isolates of free‐living amebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleri. J Euk Microbiol. 2006;53(2):121–126.
   PubMed Web of Science ®Google Scholar
• Meshnick SR. Artemisinin: mechanisms of action, resistance and toxicity. Int J Parasitol. 2002;32(13):1655–1660.
   PubMed Web of Science ®Google Scholar
• Petreaca M, Martins-Green M The dynamics of cell-ECM interactions with implications for tissue engineering. In: Principles of tissue engineering. 4th ed. Academic Press; 2014. p. 161–187. doi:10.1016/B978-0-12-398358-9.00009-4
   Google Scholar
• Lam C, Jamerson M, Cabral G, et al. Expression of matrix metalloproteinases in Naegleria fowleri and their role in invasion of the central nervous system. Microbiol. 2017;163(10):1436–1444.
   PubMed Web of Science ®Google Scholar
• Singh R, Lillard JW Jr. Nanoparticle-based targeted drug delivery. Exp Mol Patho. 2009;86(3):215–223.
   PubMed Web of Science ®Google Scholar
• Aqeel Y, Siddiqui R, Anwar A, et al. Gold nanoparticle conjugation enhances the antiacanthamoebic effects of chlorhexidine. Antimicrob Agent Chemother. 2016;60(3):1283–1288.
   Web of Science ®Google Scholar
• Rajendran K, Anwar A, Khan NA, et al. Brain-eating amoebae: silver nanoparticle conjugation enhanced efficacy of anti-amoebic drugs against Naegleria fowleri. ACS Chem Neurosci. 2017;8(12):2626–2630.
   PubMed Web of Science ®Google Scholar
• Ghosh P, Han G, De M, et al. Gold nanoparticles in delivery applications. Adv Drug Deliv Rev. 2008;60(11):1307–1315.
   PubMed Web of Science ®Google Scholar
• Chen G, Qiu H, Prasad PN, et al. Upconversion nanoparticles: design, nanochemistry, and applications in theranostics. Chem Rev. 2014;114(10):5161–5214.
   PubMed Web of Science ®Google Scholar
• Anwar A, Siddiqui R, Khan NA. Importance of theranostics in rare brain-eating amoebae infections. ACS Chem Neurosci. 2018;10(1):6–12.
   PubMed Web of Science ®Google Scholar
• Bissonnette L, Bergeron MG. Next revolution in the molecular theranostics of infectious diseases: microfabricated systems for personalized medicine. Exp Rev Mol Diagn. 2006;6(3):433–450.
   PubMed Web of Science ®Google Scholar